Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions

Analytical Biochemistry

Volumn 453, Issue 1, 2014, Pages 4-6

  Parker, Matthew W ^a   Vander Kooi, Craig W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Assay; Inhibitor; Ligand; Neuropilin; Receptor; VEGF

Indexed keywords

ASSAYS; CELL MEMBRANES; LIGANDS; MOLECULES;

ENDOTHELIAL GROWTH FACTOR; INHIBITOR; NATIONAL INSTITUTES OF HEALTH; NEUROPILIN; RECEPTOR; SMALL MOLECULE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VEGF;

DIAGNOSIS;

ANGIOGENESIS INHIBITOR; DACTINOMYCIN; DIHYDREXIDINE; DIHYDREXIDINE HYDROCHLORIDE; NEUROPILIN 2; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ZAFIRLUKAST; ZILEUTON; MOLECULAR LIBRARY; NEUROPILIN-2, HUMAN; PHENANTHRIDINE DERIVATIVE; PROTEIN BINDING; TOLUENESULFONIC ACID DERIVATIVE; VEGFC PROTEIN, HUMAN;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; FEMALE; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; LYMPH VESSEL; MICROPLATE BASED SCREENING; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING ASSAY; SIGNAL TRANSDUCTION; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; NATIONAL HEALTH ORGANIZATION; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; UNITED STATES;

DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEUROPILIN-2; PHENANTHRIDINES; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TOSYL COMPOUNDS; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84896973250     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2014.02.017     Document Type: Article

References (18)

1. S.A. Stacker, M.G. Achen, L. Jussila, M.E. Baldwin, and K. Alitalo Lymphangiogenesis and cancer metastasis Nat. Rev. Cancer 2 2002 573 583
2. L.M. Ellis The role of neuropilins in cancer Mol. Cancer Ther. 5 2006 1099 1107
3. M.W. Parker, H.F. Guo, X. Li, A.D. Linkugel, and C.W. Vander Kooi Function of members of the neuropilin family as essential pleiotropic cell surface receptors Biochemistry 51 2012 9437 9446
4. T. Karpanen, C.A. Heckman, S. Keskitalo, M. Jeltsch, H. Ollila, G. Neufeld, L. Tamagnone, and K. Alitalo Functional interaction of VEGF-C and VEGF-D with neuropilin receptors FASEB J. 20 2006 1462 1472
5. M.W. Parker, A.D. Linkugel, and C.W. Vander Kooi Effect of C-terminal sequence on competitive semaphorin binding to neuropilin-1 J. Mol. Biol. 425 2013 4405 4414
6. H.F. Guo, X. Li, M.W. Parker, J. Waltenberger, P.M. Becker, and C.W. Vander Kooi Mechanistic basis for the potent anti-angiogenic activity of semaphorin 3F Biochemistry 52 2013 7551 7558
7. C.W. Vander Kooi, M.A. Jusino, B. Perman, D.B. Neau, H.D. Bellamy, D.J. Leahy, Structural basis for ligand and heparin binding to neuropilin B domains, in: Proceedings of the National Academy of Sciences of the United States of America, 104 2007, 6152-6157.
8. P.A. Longo, J.M. Kavran, M.S. Kim, and D.J. Leahy Transient mammalian cell transfection with polyethylenimine PEI Methods Enzymol. 529 2013 227 240
9. A.R. Aricescu, W. Lu, and E.Y. Jones A time- and cost-efficient system for high-level protein production in mammalian cells Acta Crystallogr. 62 2006 1243 1250
10. M.W. Parker, P. Xu, H.F. Guo, and C.W. Vander Kooi Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition PLoS ONE 7 2012 e49177
11. A. Starzec, R. Vassy, A. Martin, M. Lecouvey, M. Di Benedetto, M. Crepin, and G.Y. Perret Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1 Life Sci. 79 2006 2370 2381
12. A. Starzec, P. Ladam, R. Vassy, S. Badache, N. Bouchemal, A. Navaza, C.H. du Penhoat, and G.Y. Perret Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex Peptides 28 2007 2397 2402
13. M.W. Parker, L.M. Hellman, P. Xu, M.G. Fried, and C.W. Vander Kooi, Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin Biochemistry 49 2010 4068 4075
14. A. Jarvis, C.K. Allerston, H. Jia, B. Herzog, A. Garza-Garcia, N. Winfield, K. Ellard, R. Aqil, R. Lynch, C. Chapman, B. Hartzoulakis, J. Nally, M. Stewart, L. Cheng, M. Menon, M. Tickner, S. Djordjevic, P.C. Driscoll, I. Zachary, and D.L. Selwood Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction J. Med. Chem. 53 2010 2215 2226
15. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73
16. N. Malo, J.A. Hanley, S. Cerquozzi, J. Pelletier, and R. Nadon Statistical practice in high-throughput screening data analysis Nat. Biotechnol. 24 2006 167 175
17. C.G. Lee, B. Ma, S. Takyar, F. Ahangari, C. Delacruz, C.H. He, and J.A. Elias Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease Proc. Am. Thorac. Soc. 8 2011 512 515
18. N. Blumberg Tumor angiogenesis factor. Speculations on an approach to cancer chemotherapy Yale J. Biol. Med. 47 1974 71 81